Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling

    Access Status
    Fulltext not available
    Authors
    Kroep, S.
    Lansdorp_Vogelaar, Iris
    Rubenstein, J.
    de Koning, H.
    Meester, R.
    Inadomi, J.
    van Ballegooijen, M.
    Date
    2015
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Kroep, S. and Lansdorp_Vogelaar, I. and Rubenstein, J. and de Koning, H. and Meester, R. and Inadomi, J. and van Ballegooijen, M. 2015. An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling. Gastroenterology. 149 (3): pp. 577-585.e4.
    Source Title
    Gastroenterology
    DOI
    10.1053/j.gastro.2015.04.045
    ISSN
    0016-5085
    URI
    http://hdl.handle.net/20.500.11937/49933
    Collection
    • Curtin Research Publications
    Abstract

    Background & Aims: Published estimates for the rate of progression from Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) vary. We used simulation modeling to reconcile published data and more accurately estimate the incidence of EAC among people with BE. Methods: We calibrated the ERASMUS/UW model (a collaboration between Erasmus Medical Center, Rotterdam, the Netherlands and the University of Washington, Seattle) for EAC to match the 0.18% annual rate of progression from population-based studies. This model was then used to simulate the design of prospective studies, introducing more endoscopic surveillance. We used the model to predict rates of progression for both types of studies and for different periods of follow-up, and compared the predicted rates with published data. Results: For the first 5 years of follow-up, the model reproduced the 0.19% mean annual rate of progression observed in population-based studies; the same disease model predicted a 0.36% annual rate of progression in studies with a prospective design (0.41% reported in published articles). After 20 years, these rates each increased to 0.63% to 0.65% annually, corresponding with a 9.1% to 9.5% cumulative cancer incidence. Between these periods, the difference between the progression rates of both study designs decreased from 91% to 5%. Conclusions: In the first 5 years after diagnosis, the rate of progression from BE to EAC is likely to more closely approximate the lower estimates reported from population-based studies than the higher estimates reported from prospective studies in which EAC is detected by surveillance. Clinicians should use this information to explain to patients their short-term and long-term risks if no action is taken, and then discuss the risks and benefits of surveillance.

    Related items

    Showing items related by title, author, creator and subject.

    • Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015
      Miller, Ted; GBD 2015 HIV Collaborators; Wang, H.; Wolock, T.; Carter, A.; Nguyen, G.; Kyu, H.; Gakidou, E.; Hay, S.; Mills, E.; Trickey, A.; Msemburi, W.; Coates, M.; Mooney, M.; Fraser, M.; Sligar, A.; Salomon, J.; Larson, H.; Friedman, J.; Abajobir, A.; Abate, K.; Abbas, K.; El Razek, M.; Abd-Allah, F.; Abdulle, A.; Abera, S.; Abubakr, I.; Abu-Raddad, L.; Abu-Rmeileh, N.; Abyu, G.; Adebiyi, A.; Adedeji, I.; Adelekan, A.; Adofo, K.; Adou, A.; Ajala, O.; Akinyemiju, T.; Akseer, N.; Al Lami, F.; Al-Aly, Z.; Alam, K.; Alam, N.; Alsfoor, D.; Aldhari, S.; Aldridge, R.; Alegretti, M.; Aleman, A.; Alemu, Z.; Alfonso-Cristancho, R.; Ali, R.; Alkerwi, A.; Alla, F.; Mohammad, R.; Al-Raddadi, S.; Alsharif, U.; Alvarez, E.; Alvis-Guzman, N.; Amare, A.; Amberbir, A.; Amegah, A.; Ammar, W.; Amrock, S.; Antonio, C.; Anwari, P.; Arnlov, J.; Artaman, A.; Asayesh, H.; Asghar, R.; Assadi, R.; Atique, S.; Atkins, L.; Avokpaho, E.; Aswathi, A.; Quintanilla, B.; Bacha, U.; Badawi, A.; Barac, A.; Barnighausen, T.; Basu, A.; Bayou, T.; Bayou, Y.; Bazargan-Hejazi, S.; Beardsley, J.; Bedi, N.; Bennett, D.; Bensenor, I.; Betsu, B.; Beyene, A.; Brainin, M.; Brazinova, A.; Bretborde, N.; Brown, A.; Burch, M.; Butt, Z.; Campuzano, J.; Cardenas, R.; Carrero, J.; Castaneda-Orjuela, C.; Rivas, J.; Catala-Lopez, F.; Chang, H.; Chang, J.; Chavan, L.; Chen, W.; Chiang, P.; Chibalabala, M.; Chisumpa, V.; Choi, J.; Christopher, D.; Ciobanu, L.; Cooper, C.; Dahiru, T.; Damtew, S.; Dandona, L.; Dandona, R.; Neves, J.; Jager, P.; Leo, D.; Degenhardt, L.; Deribe, K.; Deribew, A.; Jarlais, D.; Dharmaratne, S.; Ding, E.; Doshi, P.; Driscoll, T.; Dubey, M.; Elshrek, Y.; Elyazar, I.; Endries, A.; Ermakov, S.; Eshrati, B.; Esteghamati, A.; Faghmous, I.; Farinha, C.; Faro, A.; Farvid, M.; Farzadfar, F.; Fereshtehnejad, S.; Fernandes, J.; Fischer, F.; Fitchett, J.; Foigt, N.; Fullman, N.; Furst, T.; Gankpe, F.; Gebre, T.; Gebremedhin, A.; Gebru, A.; Geleijnse, J.; Gessner, B.; Gething, P.; Ghiwot, T.; Giroud, M.; Gishu, M.; Glaser, E.; Geonka, S.; Goodridge, A.; Gopalani, S.; Goto, A.; Gugnani, H.; Guimaraes, M.; Gupta, R.; Gupta, R.; Gupta, V.; Haagsma, J.; Hafezi-Nejad, N.; Hagan, H.; Hailu, G.; Hamadeh, R.; Hamidi, S.; Hammami, M.; Hankey, G.; Hao, Y.; Harb, H.; Harikrishnan, S.; Haro, J.; Harun, K.; Havmoeller, R.; Hedayati, M.; Heredia-Pi, I.; Hoek, H.; Horino, M.; Horita, N.; Hosgood, H.; Hoy, D.; Hsairi, M.; Hu, G.; Huang, H.; Huang, J.; Iburg, K.; Idrisov, B.; Innos, K.; Iyer, V. (2016)
      Background: Timely assessment of the burden of HIV/AIDS is essential for policy setting and programme evaluation. In this report from the Global Burden of Disease Study 2015 (GBD 2015), we provide national estimates of ...
    • Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study
      Koye, D.; Magliano, D.; Reid, Christopher; Jepson, C.; Feldman, H.; Herman, W.; Shaw, J. (2018)
      Background: Reduced glomerular filtration rate (GFR) in the absence of albuminuria is a common manifestation of chronic kidney disease (CKD) in diabetes. However, the frequency with which it progresses to end-stage kidney ...
    • The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions
      Kroep, S.; Lansdorp_Vogelaar, Iris; Van Der Steen, A.; Inadomi, J.; Van Ballegooijen, M. (2015)
      Background: Estimates for the annual progression rate from Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) vary widely. In this explorative study, we quantified how this uncertainty affects the estimates of ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.